Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 24 of 6351
-
A new roadmap to transplant: could standardizing care save more congenital heart patients?
Disease control Not yet recruitingCongenital heart disease can progress to advanced cardiac or cardiopulmonary failure requiring heart, heart-lung, or, in selected congenital conditions, bilateral lung transplantation with cardiac repair. Access to transplant evaluation and organ utilization can vary across regio…
Sponsor: CardioVision International Tech, S.A.S. de C.V. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Targeted pill aims to stall a common brain Tumor's growth
Disease control Not yet recruitingThis is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study comparing the efficacy and safety of safusidenib versus placebo in participants with residual or recurrent Grade 2 glioma (oligodendroglioma or astrocytoma) with an IDH1 mutation who have undergone…
Phase 3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New trial aims to slash deadly complications in Kids' stem cell transplants
Disease control Not yet recruitingBackground: In children with \>120 rare diseases, haematopoietic stem cell transplant (HSCT) provides a medical "reset" for the body, replacing diseased or dysfunctional bone marrow with healthy donor-derived stem cells following high-dose chemotherapy and/or radiotherapy. Howeve…
Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a targeted drug outsmart a rare blood cancer?
Disease control Not yet recruitingThe goal of this clinical trial is to assess the efficacy of teclistamab in participants with relapsed or refractory Waldenstrom's macroglobulinemia who have received prior therapy. This study also aims to assess the safety and tolerability of teclistamab, how quickly and to what…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer
Disease control Not yet recruitingThis phase III trial compares the effect of pembrolizumab to active surveillance after a surgical procedure to completely or partially remove a kidney (nephrectomy) in improving time without disease in patients with non-clear cell renal cell cancer. Immunotherapy with monoclonal …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Gene test may guide smarter chemo for pancreatic cancer
Disease control Not yet recruitingThis phase II trial tests the impact of using SMAD4-mutant status to personalize chemotherapy in treating patients with pancreatic ductal adenocarcinoma (PDAC) that can be removed by surgery (resectable) or that may be between resectable and unresectable (borderline resectable) b…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Promising antibody trial aims to halt rare bone disease in kids
Disease control Not yet recruitingThis study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at sev…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a single psilocybin dose help break meth addiction?
Disease control Not yet recruitingThis trial tests whether psilocybin-assisted treatment can help adults stop using methamphetamine. Participants receive a single oral dose of psilocybin during a supervised session, paired with brief cognitive behavioral therapy, and are followed for up to six months. The study i…
Phase 2 • Sponsor: Peter Hendricks • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a centralized team prevent more suicide attempts?
Prevention Not yet recruitingThe goal of this clinical trial is to learn the best way to provide suicide prevention care to adults receiving outpatient mental health care. The study compares two approaches based on the Zero Suicide Framework: Local Care Continuity and Centralized Care Navigation. The main q…
Sponsor: Kaiser Permanente • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
Could a second dose of dengue vaccine boost protection for kids?
Vaccine Not yet recruitingThis randomized, double-blind, three parallel-group, multicenter, phase 3b trial evaluates the safety and immunogenicity of Butantan-DV. The study compares two primary immunization regimens (Butantan-DV/Butantan-DV vs. Butantan-DV/Placebo) across both the 2-11 and 12-17 age cohor…
Phase 3 • Sponsor: Butantan Institute • Aim: Vaccine
Last updated Jul 22, 2026 00:00 UTC
-
Can a new drug tame ewing sarcoma when others fail?
Disease control Not yet recruitingThe goal of this clinical research study is to learn if new anticancer drugs or drug combinations can help to control relapsed/refractory ES, DSRCT, or SRCS.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New bladder cancer drug could spare patients from bladder removal
Disease control Not yet recruitingStudy REL-NDV01-303 is a Phase 3, open-label, multi-center study to determine the safety and efficacy of NDV-01 in adult participants with NMIBC. The study will include two cohorts: * Cohort 1: a randomized, open-label, parallel group, multi-center, Phase 3 study evaluating the …
Phase 3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can molecular markers decide who needs radiation after meningioma surgery?
Disease control Not yet recruitingThis phase III trial compares post-surgical surveillance to post-surgical radiation therapy for improving survival without disease progression in clinically low-risk patients with a grade 1 meningioma that is new or that has come back after a period of improvement (recurrent) or …
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a lung cancer drug tackle a rare, aggressive gynecological cancer?
Disease control Not yet recruitingNeuroendocrine carcinoma of the cervix (NECC) is an aggressive histological variant of cervical cancer accounting for about 1-1.5% of all cervical cancers. Small cell NEC is the most common type of NECC. This malignancy is induced by the human papillomavirus, like the other more …
Phase 2 • Sponsor: University Hospital, Strasbourg, France • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a targeted drug beat radiation for early-stage lymphoma?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if surovatamig works better than standard of care involved-site radiotherapy (ISRT) with or without rituximab to treat patients with limited-stage follicular lymphoma. It will also learn about the safety of the drug. The main questions…
Phase 3 • Sponsor: Australasian Leukaemia and Lymphoma Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Dual-Action antibody boost chemo against bile duct cancer?
Disease control Not yet recruitingThis phase II/III trial studies how well the addition of ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works when compared to usual chemotherapy and immunotherapy (durvalumab or pembrolizumab) in treating patients with biliary tract cancer that may have spread …
Phase 2/3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug sequence build stronger bones than standard care?
Disease control Not yet recruitingOsteoporosis is associated with a high risk of fractures, disability, loss of independence, and excess mortality. Zoledronic acid is an established first-line treatment in Sweden, but many patients at high fracture risk remain at substantial residual fracture risk. Short-course t…
Phase 4 • Sponsor: Sahlgrenska University Hospital • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Could a shorter drug course beat a longer one for a deadly fungal infection?
Disease control Not yet recruitingThis randomized clinical trial will evaluate the optimal duration of fluconazole therapy and timing of antiretroviral therapy initiation among HIV-infected persons with asymptomatic cryptococcal antigenemia and low cryptococcal antigen titers in Uganda. Participants with low-tit…
Phase 3 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Gene therapy before birth: a new hope for babies with GM1 disease
Disease control Not yet recruitingThis is a study for the administration of in utero AAV9 transfer in prenatally diagnosed Type I or Type II GM1.
Phase 1 • Sponsor: Tippi Mackenzie • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a drug used for overdoses boost survival after cardiac arrest?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the drug naloxone in addition to cardiopulmonary resuscitation improves outcomes of in-hospital cardiac arrets. The main questions it aims to answer are: Does naloxone improve survival after the cardiac arrest? Does naloxone improve…
Phase 2/3 • Sponsor: Region Skane • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC